Bain Capital’s $3.12bn private equity deal with Evident was the medical devices industry’s biggest cross border deal of Q3 2022 as cross border deals worth $8.1bn were announced globally in the quarter, according to GlobalData’s deals database.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 11.9% over the previous quarter and a drop of 32.6% when compared with the last four-quarter average of $11.97bn.
In terms of number of cross border deals, the sector saw a drop of 26.90% with 144 deals in Q3 2022 against the average of 197.00 deals in the last four-quarters.
In value terms, Europe led the activity with cross border deals worth $3.26bn.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDatamedical devices industry cross border deals in Q3 2022: Top deals
The top five medical devices industry cross border deals accounted for 69.4% of the overall value during Q3 2022.
The combined value of the top five cross border deals stood at $5.59bn, against the overall value of $8.1bn recorded for the quarter.
The top five medical devices industry cross border deals of Q3 2022 tracked by GlobalData were:
1) Bain Capital’s $3.12bn private equity deal with Evident
2) The $1.54bn private equity of Meridian Bioscience by SD Biosensor and SJL Partners
3) Azenta’s $468.22m acquisition deal with B Medical Systems
4) The $243.32m acquisition of Medi-Globe by DCC Healthcare
5) Breyer Capital, Cigna Ventures, DigiTx Partners, Fidelity Management & Research, Heartland Healthcare Capital, LRVHealth, Mirae Asset Capital, New Leaf Ventures, Novartis, Peter Thiel, Piper Sandler Merchant Banking, Sands Capital Management, T Rowe Price Associates, T. Rowe Price Investment Management and Vensana Capital’s $223m venture financing deal with Cleerly
